Stockscreener 앱 받기
5.63
2.60%
-0.15
시간 외 거래:
5.65
0.02
+0.36%
전일 마감가:
$5.78
열려 있는:
$5.83
하루 거래량:
551.69K
Relative Volume:
0.56
시가총액:
$260.81M
수익:
$20.72M
순이익/손실:
$-100.84M
주가수익비율:
-2.1165
EPS:
-2.66
순현금흐름:
$-78.56M
1주 성능:
-12.31%
1개월 성능:
+33.41%
6개월 성능:
-5.70%
1년 성능:
-61.78%
1일 변동 폭
$5.50
$5.9414
1주일 범위
$5.11
$6.1787
52주 변동 폭
$2.235
$17.41
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
FDMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
5.63 | 265.44M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
What makes 4D Molecular Therapeutics Inc. stock price move sharplyDividend Strategy Summary With 10-Year Outlook - Newser
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionSafe and Scalable Return Strategy Blueprint - Newser
How to build a custom watchlist for 4D Molecular Therapeutics Inc.Free Price Action Based Buy Opportunity List - Newser
Developing predictive dashboards with 4D Molecular Therapeutics Inc. dataShort-Term Sector Movement Forecast Generator - Newser
How 4D Molecular Therapeutics Inc. stock performs during market volatilityReal Time Growth Signal with Smart Setup - Newser
What technical models suggest about 4D Molecular Therapeutics Inc.’s comebackConsistent Gain Plan with AI Support - Newser
Technical analysis overview for 4D Molecular Therapeutics Inc. stockFree Portfolio Diversification Stock Ideas - Newser
Using AI based signals to follow 4D Molecular Therapeutics Inc.Long-Term Safety Investment Analysis Report - Newser
Heatmap analysis for 4D Molecular Therapeutics Inc. and competitorsFree Momentum Based Equity Trading Plan - Newser
Is 4D Molecular Therapeutics Inc. forming a reversal patternAI-Based Reversal Point Prediction Signal - Newser
Can you recover from losses in 4D Molecular Therapeutics Inc.Daily Profit Watch With Forecast Confidence - Newser
Can trapped investors hope for a rebound in 4D Molecular Therapeutics Inc.AI Enhanced Strategy for Portfolio Growth - Newser
Will 4D Molecular Therapeutics Inc. price bounce be sustainableReal-Time Entry Signals for Top Stocks - Newser
Will earnings trigger a reversal in 4D Molecular Therapeutics Inc.Volume Spike Detection for Early Breakouts - Newser
What makes 4D Molecular Therapeutics Inc. stock attractive to long term investorsFree Real Market Momentum Signal Generator - Newser
4D Molecular Therapeutics to Participate in H.C. Wainwright Ophthalmology Virtual Conference - AInvest
4D Molecular Therapeutics shares fall 1.92% premarket ahead of H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
Published on: 2025-08-07 03:01:11 - Newser
4D Molecular Therapeutics (FDMT) to Release Earnings on Thursday - Defense World
4D Molecular Therapeutics shares fall 2.73% intraday after announcing participation in H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
Volatility clustering patterns for 4D Molecular Therapeutics Inc.Short-Term Sector Movement Forecast Generator - Newser
Using fundamentals and technicals on 4D Molecular Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser
4D Molecular Therapeutics Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Fibonacci Support Holding Strong in 4D Molecular Therapeutics Inc.Conservative Long Term Growth Plans Under Review - beatles.ru
Why is 4D Molecular Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent profits with proven methods - Jammu Links News
4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at Chardan Capital - Defense World
Is 4D Molecular Therapeutics Inc. a growth stock or a value stockProven strategies for superior portfolio growth - Jammu Links News
What is the dividend policy of 4D Molecular Therapeutics Inc. stockGet daily expert analysis on top stocks - Jammu Links News
Is 4D Molecular Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Capital Preserving Trade Plan Templates - Newser
What is the risk reward ratio of investing in 4D Molecular Therapeutics Inc. stockExplosive capital gains - Jammu Links News
What are 4D Molecular Therapeutics Inc. company’s key revenue driversCapitalize on fast-growing investment opportunities - Jammu Links News
Does 4D Molecular Therapeutics Inc. stock perform well during market downturnsRapid profit acceleration - Jammu Links News
Is 4D Molecular Therapeutics Inc. stock overvalued or undervaluedInvest smarter with data-backed trading alerts - Jammu Links News
What are the technical indicators suggesting about 4D Molecular Therapeutics Inc.Spectacular growth rates - Jammu Links News
When is 4D Molecular Therapeutics Inc. stock expected to show significant growthMassive stock growth - Jammu Links News
4D Molecular Therapeutics Inc. stock prediction for this weekLow Drawdown Picks with Weekly Updates - Newser
4D Molecular Therapeutics Showcases Positive Trial Results, Charts New Growth Trajectory - timothysykes.com
4D Molecular (FDMT) Stock Climbs Following Promising Retina Therapy Data - Stocks Telegraph
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study - 富途牛牛
How volatile is 4D Molecular Therapeutics Inc. stock compared to the marketEntry Signal Forecasts With Low Risk - Jammu Links News
4D Molecular: Time to Buy After Recent Surge? - StocksToTrade
4D Molecular Therapeutics: A Market Shift? - timothysykes.com
4D Molecular Therapeutics shares rise 30.44% premarket after presenting positive 60-week results for 4D-150. - AInvest
Chardan Capital Maintains Buy on 4D Molecular, Raises PT to $25 - AInvest
4D Molecular Therapeutics stock soars after positive DME trial results By Investing.com - Investing.com Canada
Will a bounce in 4D Molecular Therapeutics Inc. offer an exitPrice Action Trading with Volume Confirmation - Newser
4D Molecular Therapeutics Shares Surge 50.89% on Positive Clinical Trial Results - AInvest
4D Molecular Therapeutics (FDMT) Shares Soar 37.78% on Positive Clinical Trial Results - AInvest
4D Molecular Therapeutics shares rise 56% premarket after presenting positive 60-week results for 4D-150. - AInvest
4D Molecular (FDMT) Shows Promising Results in Clinical Trial fo - GuruFocus
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update - GlobeNewswire
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):